The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector.
Posts Tagged ‘Lilly Eli & Co (LLY)’
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Celgene Corporation (CELG), Bristol-Myers Squibb Co (BMY): One Drug Dramatically Reshaping Pancreatic Cancer Treatment
A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don't only have to consider the actions of the drug on the body.
Express Scripts Holding Company (ESRX), Novo Nordisk A/S (ADR) (NVO), Walgreen Company (WAG): Don’t Mess With This 800-Pound Gorilla in the Pharma Space
Express Scripts Holding Company (NASDAQ:ESRX) -- the largest pharmacy benefit manager, or PBM, in America -- is also one of the most important companies in the health care ...
Pfizer Inc. (PFE), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Two Lucrative Drug Markets You Should Avoid
You really don't need both. There are enough people with rheumatoid arthritis or high cholesterol, for example, to have multiple blockbuster drugs that treat the diseases.
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we've discussed many of the biggest risk factors associated with some of the leading causes of death in the United States -- heart disease, cancer...
Will This Destroy MannKind Corporation (MNKD)?
The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly.
Tyson Foods, Inc. (TSN), Merck & Co., Inc. (MRK): Food Companies Suspend Growth Meds for Animals
Top beef producer Tyson Foods, Inc. (NYSE:TSN) has decided to stop buying cattle that are fed the growth additive Zilmax, produced by Merck & Co., Inc. (NYSE:MRK).
MannKind Corporation (MNKD): To Infinity And Beyond?
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
Pfizer Inc. (PFE): The Procter & Gamble Company (PG)’s Fall Can’t Stop the Dow Jones Industrial Average (.DJI)’s Bounce
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS), Shire PLC (ADR) (SHPG): A Closer Look at the Controversial Market Growth of ADHD Treatments
The existence of ADHD, or attention deficit hyperactivity disorder, has been a hot-button topic since the 1970s.
Roche Holding Ltd. (ADR) (RHHBY), Eli Lilly & Co. (LLY): Understanding the Massive Market Potential of Monoclonal Antibodies
Over the past several years, monoclonal antibodies have revolutionized cancer treatments.
Tyson Foods, Inc. (TSN), Smithfield Foods, Inc. (SFD): Merck & Co., Inc. (MRK) Buried by Industry Beef
Like a pebble rolling downhill and starting an avalanche, the decision by Tyson Foods, Inc.
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Sanofi SA (ADR) (SNY): Positive News for This Troubled Pharma Player
Eli Lilly & Co. (NYSE:LLY) recently rose nearly 3% following positive phase 3 results for cancer drug necitumumab.
Alkermes Plc (ALKS), Eli Lilly & Co. (LLY), AstraZeneca plc (ADR) (AZN): Tackling Pain and Addiction
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Peregrine Pharmaceuticals (PPHM), Sanofi SA (ADR) (SNY): Is This Experimental Lung Cancer Drug Back on Track?
Peregrine Pharmaceuticals (NASDAQ:PPHM), a developmental stage biotech focusing on oncology treatments, recently announced that its lead drug candidate, bavituximab, was heading...
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Forest Laboratories, Inc. (FRX): The Past, Present, and Future of Alzheimer’s Treatments
Editor’s Note: A previous version of this post incorrectly stated that Eli Lilly’s experimental drug solanezumab is a BACE inhibitor.
Eli Lilly & Co. (LLY): Is It Destined for Greatness?
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Valeant Pharmaceuticals Intl Inc (VRX), GlaxoSmithKline plc (ADR) (GSK) – CAPScall of the Week: Raptor Pharmaceutical Corp. (RPTP)
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S.
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Allergan, Inc. (AGN): Three Companies Working to Make Your Migraines Milder
The National Headache Foundation (yes, there is such an organization) says that around 30 million Americans suffer from migraines.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Will Zoetis Earnings Deliver on Post-Spinoff Growth?
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity.
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS): Is This Company Getting Ahead of Itself?
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Bristol-Myers Squibb Co (BMY): These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies.
Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
Intel Corporation (INTC), Chevron Corporation (CVX), Eli Lilly & Co. (LLY): What You Need to Know About Dividends
When it comes to stock investing, conventional thinking dictates that returns are all about capital appreciation.
Is More Patent Pain Headed Merck & Co., Inc. (MRK)’s Way?
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma's largest companies, but this health care leader has had a tough go recently.
Three Things You Need to Know From Merck & Co., Inc. (MRK)’s Q2 Earnings
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
AstraZeneca plc (ADR) (AZN) and Bristol Myers Squibb Co. (BMY): 2 Keys to Success for This Diabetes Drug’s Second Chance
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Abbott Laboratories (ABT), Eli Lilly & Co. (LLY): Healthcare Stocks to Consider Buying
Note: This article has been amended to remove TRADJENTA as Eli Lilly & Co.
Bristol Myers Squibb Co. (BMY), AstraZeneca plc (ADR) (AZN): Expanding P/E Saved This Pharma Investment
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
Eli Lilly & Co. (LLY), Seagate Technology PLC (STX), Reynolds American, Inc. (RAI): You Should Be Concerned With These 4 Post-Earnings Stocks
Earnings can change the outlook for a company, good or bad, and they can also validate an opinion that you already may have.
Are Eli Lilly & Co. (LLY) Earnings Headed Down?
Eli Lilly & Co. (NYSE:LLY) will release its quarterly report tomorrow, and recent share-price declines show that investors are somewhat nervous about the company's prospects.
Eli Lilly & Co. (LLY): What Does the Patent Cliff Mean for This Drugmaker?
For Eli Lilly & Co. (NYSE:LLY), history is repeating itself once again.
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it's earnings season again.
Three Key Takeaways From Johnson & Johnson (JNJ)’s Q2
Johnson & Johnson (NYSE:JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion.
The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
Eli Lilly & Co. (LLY), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The 3 Most Commonly Diagnosed Mental Disorders
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Drug Deal Can Only Help VIVUS, Inc. (VVUS) So Much
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Allergan, Inc. (AGN): A New Migraine Therapy That Can Address a Major Demand
One-fourth of all migraine patients suffer nasty side effects from the market's dominant migraine-fighting treatments.
Spectrum Pharmaceuticals, Inc. (SPPI): Is This Biotech for Sale?
For the last five years, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) CEO Rajesh Shrotriya has always insisted that Spectrum Pharmaceuticals, Inc.
GlaxoSmithKline plc (ADR) (GSK): Why You Should Buy This European Healthcare Company
Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and high dividend yields.
